Enzyme Replacement TherapySpruce Biosciences licensed tralesinidase alfa, an enzyme replacement therapy, which has 1st to market potential.
Potential RevenueIf approved, the program is potentially eligible for a Priority Review Voucher, which could bring in additional funding if monetized.
Regulatory ApprovalThe FDA confirmed that HS-NRE is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for Accelerated Approval.